These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 22614978)

  • 1. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
    Lee JH; Choi JW; Kim YS
    Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
    Saldanha G; Potter L; Daforno P; Pringle JH
    Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
    Colombino M; Lissia A; Capone M; De Giorgi V; Massi D; Stanganelli I; Fonsatti E; Maio M; Botti G; Caracò C; Mozzillo N; Ascierto PA; Cossu A; Palmieri G
    J Transl Med; 2013 Aug; 11():202. PubMed ID: 23987572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of BRAF and NRAS mutations in uveal melanoma.
    Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
    Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
    Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
    Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
    Omholt K; Karsberg S; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2002 Nov; 8(11):3468-74. PubMed ID: 12429636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
    Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
    Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
    Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
    Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.